The decision to block Moderna's application was made personally by CBER Director Dr. Vinay Prasad, against the recommendation of the FDA's vaccine office staff. This unusual top-down intervention bypasses standard scientific review processes, raising concerns about politicization and the integrity of the regulatory process.

The FDA is creating a transparency paradox. It is increasingly publishing complete response letters (CRLs), giving insight into why drugs are rejected. Simultaneously, it has drastically cut the number of public advisory committee (AdCom) meetings held before approval decisions, reducing public input and pre-decision transparency.

Biotech companies are intensely reliant on the FDA for approvals, making it nearly impossible to enforce legal agreements or challenge the agency publicly, even when wronged. This "repeat relationship" means the FDA ultimately holds all the power, making any direct conflict a perilous decision for a company.

Disagreements between FDA review teams and senior leadership, like CBER head Vinay Prasad, create contradictory guidance for drug sponsors. Companies follow the review team's advice, only to be overruled by leadership, leading to wasted resources, delayed approvals, and significant frustration.

Replimune's core argument against the FDA's rejection is that the entire melanoma medical community is demanding access to their drug. The company highlights that 22 trial investigators and major medical institutions wrote letters to the FDA, attempting to use the weight of expert opinion to overrule the regulator's objections.

Bio is creating a formal system for biotech companies to report challenges with the FDA. Bio will synthesize this feedback monthly and present it directly to FDA leadership, creating a novel channel to elevate systemic issues and improve accountability.

FDA CBER Director Vinay Prasad is reportedly overriding staff recommendations not just in his own center (vaccines), but also in CEDAR (drugs), as seen in the Disc Medicine case. This consolidation of decision-making power in one individual is making FDA approvals far more unpredictable for drug developers.

Recent events, like Moderna's rescinded 'refusal to file' letter, reveal that alignment with FDA staff on trial design is no guarantee. Senior leaders, notably Vinay Prasad, are reportedly overturning prior agreements, creating extreme uncertainty and making it impossible for companies to trust the regulatory guidance they receive.

The FDA advised against a single-arm study unless data was "sufficiently compelling." Replimune argues the FDA's subsequent actions—granting priority review and not objecting to the filing—implied the data met this bar, making the final rejection based on the study design feel disingenuous and like a retrospective goalpost shift.